Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

Early-onset Therapy-related Myelodysplastic Syndrome Originating from Prolonged Myelosuppression after Fludarabine-based Therapy

(2014) Sho Yamazaki et al.   INTERNAL MEDICINE

Acute myeloid leukemia with 11q23/MLL rearrangement after ‘FCR’ regimen for chronic lymphocytic leukemia

(2012) Nadav Sarid et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

(2011) X. C. Badoux et al.   BLOOD

Update on Therapy of Chronic Lymphocytic Leukemia

(2011) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

(2010) D A Carney et al.   LEUKEMIA

Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy

(2010) L Ysebaert et al.   LEUKEMIA

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD